# EDGAR Filing Document

**Accession Number:** 0000944148
**File Stem:** 0000944148-25-000020
**Filing Date:** 2025-10
**Character Count:** 51510
**Document Hash:** 1882dee9a300b5459ad68afcd1b5e84f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000944148-25-000020.hdr.sgml**: 20251029

**ACCESSION NUMBER**: 0000944148-25-000020

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20251029

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251029

**DATE AS OF CHANGE**: 20251029

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CBIZ, Inc.
- **CENTRAL INDEX KEY:** 0000944148
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-BUSINESS SERVICES, NEC [7389]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 222769024
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32961
- **FILM NUMBER:** 251430230

**BUSINESS ADDRESS:**
- **STREET 1:** 5959 ROCKSIDE WOODS BLVD N.
- **STREET 2:** SUITE 600
- **CITY:** INDEPENDENCE
- **STATE:** OH
- **ZIP:** 44131
- **BUSINESS PHONE:** 2164479000

**MAIL ADDRESS:**
- **STREET 1:** 5959 ROCKSIDE WOODS BLVD N.
- **STREET 2:** SUITE 600
- **CITY:** INDEPENDENCE
- **STATE:** OH
- **ZIP:** 44131

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CENTURY BUSINESS SERVICES INC
- **DATE OF NAME CHANGE:** 19980218

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INTERNATIONAL ALLIANCE SERVICES INC
- **DATE OF NAME CHANGE:** 19961031

?xml version='1.0' encoding='ASCII'? cbz-20251029

  

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**October 29, 2025**

**Date of Report (Date of earliest event reported)**

**CBIZ, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **1-32961** | **22-2769024** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission<br>File Number)** | **(IRS Employer<br>Identification No.)** |

---

**5959 Rockside Woods, Blvd. N. Suite 600**

**Independence, Ohio 44131**

**(Address of principal executive offices, including zip code)**

**216-447-9000**

**(Registrant's telephone number, including area code)**

**Note Applicable** 

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>On which registered** |
| **Common Stock, $0.01 par value** | **CBZ** | **New York Stock Exchange** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

☐&nbsp;&nbsp;&nbsp;&nbsp;Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition**

On October 29, 2025, CBIZ, Inc. (the "Company") issued a press release announcing its financial results for the three and nine months ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The exhibit contains, and may implicate, forward-looking statements regarding the Company and include cautionary statements identified important factors that could cause actual results to differ materially from those anticipated.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits**

(d)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits

<u>[99.1](q32025earningrelease.htm)</u>&nbsp;&nbsp;&nbsp;&nbsp;Press Release of CBIZ, Inc. dated October 29, 2025, announcing its financial results for the three and nine months &nbsp;&nbsp;&nbsp;&nbsp;ended September 30, 2025.

104&nbsp;&nbsp;&nbsp;&nbsp;Cover Page Interactive Data File (embedded within the Inline XBRL document)

------

**SIGNATURES:**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 29, 2025

CBIZ, Inc.

---

| | |
|:---|:---|
| By: | /s/ Brad Lakhia |
| Name: | Brad Lakhia |
| Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| ![cbiznewlogoa.jpg](cbiznewlogoa.jpg) | ![prpicturea.jpg](prpicturea.jpg) |
| **FOR IMMEDIATE RELEASE** | |

---

**<br>CBIZ REPORTS THIRD QUARTER AND NINE MONTH 2025 RESULTS**

---

| |
|:---|
| **THIRD QUARTER HIGHLIGHTS:** |
| &nbsp;&nbsp;&nbsp;&nbsp;• TOTAL REVENUE OF $693.8M, UP 58.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;• NET INCOME OF $30.1M, DOWN 14.1%; GAAP EPS OF $0.48, DOWN 31.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;• ADJUSTED EBITDA OF $120.0M, UP 57.4%; ADJUSTED DILUTED EPS OF $1.01, UP 8.5%  |
| **NINE MONTH HIGHLIGHTS:** |
| &nbsp;&nbsp;&nbsp;&nbsp;• TOTAL REVENUE OF $2.2B, UP 63.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;• NET INCOME OF $194.9M, UP 47.9%; GAAP EPS OF $3.06, UP 16.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;• ADJUSTED EBITDA OF $475.6M, UP 92.9%; ADJUSTED DILUTED EPS OF $4.27, UP 35.6% |

---

CLEVELAND (October 29, 2025) – CBIZ, Inc., (NYSE: CBZ) ("CBIZ" or the "Company"), a leading national professional services advisor, today announced results for the third quarter ended September 30, 2025.

"We are pleased with our third quarter results, which were largely in line with our expectations. Our core, recurring essential businesses continued to perform well, and improved market conditions also resulted in improved growth within our non-recurring businesses," said Jerry Grisko, CBIZ President and CEO.

"We are seeing strong validation of the Marcum acquisition, including better than expected synergies, and are well positioned to drive sustainable long-term growth as we bring our unique value proposition to our clients and prospects in the high-growth U.S. middle market."

For the third quarter of 2025, CBIZ recorded revenue of $693.8 million, an increase of $254.9 million, or 58.1%, compared with $438.9 million reported for the same period in 2024. Net income was $30.1 million, or $0.48 per diluted share, for the third quarter of 2025, compared with $35.1 million, or $0.70 per diluted share, for the same period a year ago.

Excluding acquisition-related integration expenses, amortization of intangible assets, and other non-recurring gains and losses, Adjusted net income was $63.5 million in the third quarter of 2025, compared with Adjusted net income of $46.9 million for the same period a year ago. Adjusted earnings per diluted share were $1.01 for the third quarter of 2025, an increase of 8.5%, compared with Adjusted earnings per diluted share of $0.93 for the same period a year ago. Adjusted EBITDA for the third quarter of 2025 was $120.0 million, up 57.4%, compared with $76.3 million for the same period in 2024.

For the nine months ended September 30, 2025, CBIZ recorded revenue of $2,215.3 million, an increase of $862.1 million or 63.7%, over the $1,353.2 million recorded for the same period in 2024. Net income was

Page 1 of 16

**NYSE: CBZ** ● **<u>www.cbiz.com</u>** ● X: **@cbz**

------

$194.9 million, or $3.06 per diluted share, for the nine months ended September 30, 2025, compared with $131.8 million, or $2.62 per diluted share, for the same period a year ago.

For the nine months ended September 30, 2025, Adjusted net income was $271.9 million, compared with Adjusted net income of $158.6 million for the same period a year ago. Adjusted earnings per diluted share was $4.27 for the nine months ended September 30, 2025, an increase of 35.6%, compared with Adjusted earnings per diluted share of $3.15 for the same period a year ago. Adjusted EBITDA for the nine months ended September 30, 2025, was $475.6 million, up 92.9%, compared with $246.5 million for the same period in 2024.

**2025 Outlook**

The Company expects:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total revenue within a range of $2.8 billion to $2.95 billion

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Effective tax rate of approximately 29%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Weighted average fully diluted share count within a range of 64.5 to 65.0 million shares

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GAAP fully diluted earnings per share to be within a range of $1.97 to $2.02

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted fully diluted earnings per share within a range of $3.60 to $3.65

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA within a range of $450 million to $456 million

**Conference Call**

CBIZ will host a conference call today at 5 p.m. (ET) to discuss its third quarter financial results. The call will be webcast, and an archived replay will be available at <u>https://cbiz.gcs-web.com/investor-overview.</u> Participants can register for the conference call at <u>https://dpregister.com/sreg/10203902/1002b28f89e</u>.

**About CBIZ**

CBIZ, Inc. (NYSE: CBZ) is a leading professional services advisor to middle-market businesses nationwide. With industry knowledge and expertise in accounting, tax, advisory, benefits, insurance, and technology, CBIZ delivers actionable insights to help clients anticipate what is next and discover new ways to accelerate growth. CBIZ has more than 10,000 team members across more than 160 locations in 22 major markets coast to coast. For more information, visit <u>www.cbiz.com</u>.

**Forward-Looking Statements**

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical fact included in this release, including, without limitation, our "2025 Outlook," regarding our financial position, business strategy and plans and objectives for future performance are forward-looking statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts. Forward-looking statements are commonly identified by the use of such terms and phrases as "will," "could," "can," "may," "strive," "hope," "intend," "believe," "estimate," "continue," "plan," "expect," "project," "anticipate," "outlook," "foreseeable future," "seek" and words or phrases of similar import in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, future performance or results of current and anticipated services, sales efforts, expenses, and financial results.

Page 2 of 16

**NYSE: CBZ** ● **<u>www.cbiz.com</u>** ● X: **@cbz**

------

From time to time, we may also provide oral or written forward-looking statements in other materials we release to the public. Any or all of our forward-looking statements in this release and in any other public statements that we make, are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to: payments on accounts receivable may be slower than expected, or amounts due on receivables or notes may not be fully collectible; our business could be adversely affected if Marcum LLP ("Marcum") does not perform to our expectations or we underestimate the liabilities we have assumed; we are dependent on the services of our executive officers, and other key employees, the loss of whom may have a material adverse effect on our business, financial condition and results of operations; restrictions imposed by independence requirements and conflict of interest rules, as well as the nature and terms of our current administrative service agreements, limit our ability to provide services to clients of the attest firms with which we have contractual relationships and the ability of such attest firms to provide attestation services to our clients; our goodwill and other intangible assets could become impaired, which could lead to material non-cash charges against earnings and a material impact on our results of operations and financial condition; certain liabilities resulting from acquisitions are estimated and could lead to a material impact on our results of operations; we may fail to realize the anticipated benefits of acquisitions, or they may prove disruptive and could result in the combined business failing to meet our expectations; recent Securities & Exchange Commission ("SEC") and Public Company Accounting Oversight Board sanctions against Marcum may adversely impact our performance and reputation; if we are unable to implement and maintain effective internal control over financial reporting following the acquisition of Marcum (the "Transaction"), we may fail to prevent or detect material misstatements in our financial statements, in which case investors could lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock may decline; we may not be able to acquire and finance additional businesses, which could limit our ability to pursue our business strategy; we will incur transaction, integration, and restructuring costs in connection with our acquisition program; governmental regulations and interpretations are subject to changes, which could have a material adverse effect on our financial condition; continuing uncertainty in the current economic and geopolitical environment could lead to continuing softness in demand for certain of our services; changes in the United States healthcare environment, including new healthcare legislation, may adversely affect the revenue and margins in our healthcare benefit business; we are subject to risks relating to processing customer transactions for our payroll and other transaction processing businesses; cyberattacks or other security breaches involving our computer systems or the systems of one or more of our vendors could materially and adversely affect our business; we are subject to risk as it relates to software that we license from third parties; we are reliant on information processing systems and any failure or disruptions of these systems could have a material adverse effect on our business, financial condition and results of operations; we could be held liable for errors and omissions; the business services industry is competitive and fragmented, if we are unable to compete effectively, our business, financial condition and results of operations could be negatively impacted; given our levels of share-based compensation, our tax rate may vary significantly depending on our stock price; rapid technological changes could significantly impact our competitive position, client relationships and operating results and our ability to realize the anticipated benefits of the Transaction; climate change legislation or regulations restricting emissions of greenhouse gases could result in increased operating costs; the adverse impact of legislative and regulatory changes in the U.S. and globally, including as a result of the One Big Beautiful Bill Act, on the our tax rate, accounting practices, operations and results; the widespread outbreak of a communicable illness or any other public health crisis could adversely affect our business, financial condition and results of operations; we require a significant amount of cash for interest payments on our debt and to expand our business as planned; terms of our amended and restated credit agreement providing for $2.0 billion in senior secured credit facilities, consisting of a $1.4 billion term loan and $600.0 million revolving credit facility, could adversely affect our ability to run our business and/or reduce stockholder returns; our failure to satisfy covenants in our debt

Page 3 of 16

**NYSE: CBZ** ● **<u>www.cbiz.com</u>** ● X: **@cbz**

------

instruments could cause a default under those instruments; our increased leverage following the Transaction may adversely impact our business; we may be more sensitive to revenue fluctuations than other companies, which could result in fluctuations in the market price of our common stock; the significant number of shares issuable as the stock consideration in the Transaction may adversely impact our stock price; the future issuance of additional shares could adversely affect the price of our common stock; there is volatility in our stock price; and the price of our common stock could be adversely impacted if we do not perform to expectations following the Transaction.

Such forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Should one or more of these risks materialize, or should the underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated, projected or implied.

Consequently, no forward-looking statement can be guaranteed. A more detailed description of risk factors may be found in our periodic filings with the SEC, including in "Item 1A. Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2024. All forward-looking statements made in this release are made only as of the date hereof, and we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are advised, however, to consult any further disclosures we make on related subjects in the current, quarterly, periodic and annual reports we file with the SEC.

**Non-GAAP Financial Measures**

To supplement our consolidated financial statements, which are prepared and presented in accordance with United States Generally Accepted Accounting Principles ("GAAP"), we also present Adjusted Net Income (Loss), Adjusted Diluted Earnings Per Share ("EPS"), and Adjusted EBITDA, which are non-GAAP measures. These non-GAAP measures are adjusted to exclude the impact of the Transaction, integration costs, amortization of acquired intangible assets, and other significant non-operating related gains and losses management does not consider ongoing in nature.

The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. We use these non-GAAP financial measures for financial and operational decision-making, and to evaluate results relative to employee compensation targets. We believe that these non-GAAP financial measures provide meaningful supplemental information to stockholders, debt holders, and other interested parties in assessing our performance. These non-GAAP financial measures also facilitate management's internal comparisons to our historical performance by excluding significant acquisition expenses, certain one-time non-recurring items, and gains and losses that management does not consider ongoing in nature. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key measures used by management in its financial and operational decision-making and (2) they are used by our stockholders and analyst community to determine the health of our business.

Management provides specific information regarding the GAAP amounts excluded from or included in these non-GAAP financial measures. Additionally, management provides reconciliations of these non-GAAP financial measures to their most comparable financial measures in accordance with GAAP. Please see the sections captioned "GAAP Reconciliation" within the Appendix for the reconciliations.

Page 4 of 16

**NYSE: CBZ** ● **<u>www.cbiz.com</u>** ● X: **@cbz**

------

**CBIZ, INC.**

**FINANCIAL HIGHLIGHTS (UNAUDITED)**

**THREE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024**

***(In thousands, except percentages and per share data)***

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** |
| | **2025** | % | **2024** | % |
| **Revenue** | $**693818** | **100.0%** | $**438884** | **100.0%** |
| Operating expenses <sup>(1)</sup> | 603689 | 87.0 | 365971 | 83.4 |
| **Gross margin** | **90129** | **13.0** | **72913** | **16.6** |
| Corporate general and administrative expenses <sup>(1)</sup> | 31265 | 4.5 | 23227 | 5.3 |
| **Operating income** | **58864** | **8.5** | **49686** | **11.3** |
| Other (expense) income: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense | (27960) | (4.0) | (4968) | (1.1) |
| &nbsp;&nbsp;&nbsp;Gain on sale of operations, net | 1124 | 0.2 | 4953 | 1.1 |
| &nbsp;&nbsp;&nbsp;Other income, net <sup>(1) (2)</sup> | 8378 | 1.2 | 1300 | 0.3 |
| Total other expense, net | (18458) | (2.7) | 1285 | 0.3 |
| **Income before income tax expense** | **40406** | **5.8** | **50971** | **11.6** |
| Income tax expense | 10260 |  | 15887 |  |
| **Net income** | $**30146** | **4.3%** | $**35084** | **8.0%** |
| **Diluted earnings per share** | $**0.48** |  | $**0.70** |  |
| Diluted weighted average common shares outstanding | 62699 |  | 50401 |  |
| **Other data:** |  |  |  |  |
| Adjusted EBITDA <sup>(3)</sup> | $120028 | 17.3% | $76256 | 17.4% |
| Adjusted Diluted EPS <sup>(3)</sup> | $1.01 |  | $0.93 |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)CBIZ sponsors a deferred compensation plan, under which a CBIZ employee's compensation deferral is held in a rabbi trust and invested as directed by the employee. Income and expenses related to the deferred compensation plan are included in "Operating expenses" and "Corporate general and administrative expenses," and are directly offset by deferred compensation gains or losses in "Other income (expense), net." The deferred compensation plan has no impact on "Income before income tax expense."

Income and expenses related to the deferred compensation plan for the three months ended September 30, 2025, and 2024, are as follows (in thousands, except percentages):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** |
| | **2025** | **% of Revenue** | **2024** | **% of Revenue** |
| Operating expenses | $7847 | 1.1% | $7305 | 1.7% |
| Corporate general & administrative expenses | 1076 | 0.2% | 1064 | 0.2% |
| Other income, net | 8923 | 1.3% | 8369 | 1.9% |

---

Page 5 of 16

**NYSE: CBZ** ● **<u>www.cbiz.com</u>** ● X: **@cbz**

------

Excluding the impact of the above-mentioned income and expenses related to the deferred compensation plan, the operating results for the three months ended September 30, 2025, and 2024, are as follows (in thousands, except percentages):

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** |
| | **2025** | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** | **2024** |
| | **As Reported** | **Deferred Compensation Plan** | **Adjusted** | **% of Revenue** | **As Reported** | **Deferred Compensation Plan** | **Adjusted** | **% of Revenue** |
| Gross margin | $90129 | $7847 | $97976 | 14.1% | $72913 | $7305 | $80218 | 18.3% |
| Operating income | 58864 | 8923 | 67787 | 9.8% | 49686 | 8369 | 58055 | 13.2% |
| Other income, net | 8378 | (8923) | (545) | (0.1)% | 1300 | (8369) | (7069) | (1.6)% |
| Income before income tax expense | 40406 |  | 40406 | 5.8% | 50971 |  | 50971 | 11.6% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Included in "Other income, net" for the three months ended September 30, 2025, and 2024, is expense of $0.5 million and $5.7 million, respectively, related to net changes in the fair value of contingent consideration related to CBIZ's prior acquisitions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)Refer to the schedules reconciling Adjusted Diluted EPS and Adjusted EBITDA to the most directly comparable GAAP financial measures at the end of this release, and for additional information as to the usefulness of the non-GAAP financial measures to stockholders and investors.

Page 6 of 16

**NYSE: CBZ** ● **<u>www.cbiz.com</u>** ● X: **@cbz**

------

**CBIZ, INC.**

**FINANCIAL HIGHLIGHTS (UNAUDITED)**

**NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024**

***(In thousands, except percentages and per share data)***

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | % | **2024** | % |
| **Revenue** | $**2215328** | **100.0%** | $**1353193** | **100.0%** |
| Operating expenses <sup>(1)</sup> | 1809188 | 81.7 | 1108824 | 81.9 |
| **Gross margin** | **406140** | **18.3** | **244369** | **18.1** |
| Corporate general and administrative expenses <sup>(1)</sup> | 86972 | 3.9 | 63988 | 4.7 |
| **Operating income** | **319168** | **14.4** | **180381** | **13.4** |
| Other (expense) income: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense | (80983) | (3.7) | (15363) | (1.1) |
| &nbsp;&nbsp;&nbsp;Gain on sale of operations, net | 1124 | 0.1 | 4953 | 0.4 |
| &nbsp;&nbsp;&nbsp;Other income, net <sup>(1) (2)</sup> | 31786 | 1.4 | 13207 | 1.0 |
| Total other (expense) income, net | (48073) | (2.2) | 2797 | 0.3 |
| **Income before income tax expense** | **271095** | **12.2** | **183178** | **13.7** |
| Income tax expense | 76234 |  | 51417 |  |
| **Net income** | $**194861** | **8.8%** | $**131761** | **9.7%** |
| **Diluted earnings per share** | $3.06 |  | $2.62 |  |
| Diluted weighted average common shares outstanding | 63609 |  | 50359 |  |
| **Other data:** |  |  |  |  |
| Adjusted EBITDA <sup>(3)</sup> | $475597 | 21.5% | $246491 | 18.2% |
| Adjusted Diluted EPS <sup>(3)</sup> | $4.27 |  | $3.15 |  |

---

Page 7 of 16

**NYSE: CBZ** ● **<u>www.cbiz.com</u>** ● X: **@cbz**

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)CBIZ sponsors a deferred compensation plan, under which a CBIZ employee's compensation deferral is held in a rabbi trust and invested as directed by the employee. Income and expenses related to the deferred compensation plan are included in "Operating expenses" and "Corporate general and administrative expenses," and are directly offset by deferred compensation gains or losses in "Other income (expense), net." The deferred compensation plan has no impact on "Income before income tax expense."

Income and expenses related to the deferred compensation plan for the nine months ended September 30, 2025, and 2024, are as follows (in thousands, except percentages):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **% of Revenue** | **2024** | **% of Revenue** |
| Operating expenses | $17132 | 0.8% | $18164 | 1.3% |
| Corporate general and administrative expenses | 2415 | 0.1% | 2444 | 0.2% |
| Other income, net | 19547 | 0.9% | 20608 | 1.5% |

---

Excluding the impact of the above-mentioned income and expenses related to the deferred compensation plan, the operating results for the nine months ended September 30, 2025, and 2024, are as follows (in thousands, except percentages):

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** | **2024** |
| | **As Reported** | **Deferred Compensation Plan** | **Adjusted** | **% of Revenue** | **As Reported** | **Deferred Compensation Plan** | **Adjusted** | **% of Revenue** |
| Gross margin | $406140 | $17132 | $423272 | 19.1% | $244369 | $18164 | $262533 | 19.4% |
| Operating income | 319168 | 19547 | 338715 | 15.3% | 180381 | 20608 | 200989 | 14.9% |
| Other income, net | 31786 | (19547) | 12239 | 0.6% | 13207 | (20608) | (7401) | (0.5)% |
| Income before income tax expense | 271095 |  | 271095 | 12.2% | 183178 |  | 183178 | 13.5% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Included in "Other income, net" for the nine months ended September 30, 2025, and 2024, is expense of $2.0 million and $6.3 million, respectively, related to net changes in the fair value of contingent consideration related to CBIZ's prior acquisitions. Additionally, during the nine months ended September 30, 2025 the Company recorded a $12.5 million gain from a legal settlement. <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)Refer to the schedules reconciling Adjusted Diluted EPS and Adjusted EBITDA to the most directly comparable GAAP financial measures at the end of this release and for additional information as to the usefulness of the non-GAAP financial measures to stockholders and investors.

Page 8 of 16

**NYSE: CBZ** ● **<u>www.cbiz.com</u>** ● X: **@cbz**

------

**CBIZ, INC.**

**FINANCIAL HIGHLIGHTS (UNAUDITED)**

**<u>SELECT SEGMENT DATA</u>**

***(In thousands)***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Revenue** |  |  |  |  |
| Financial Services | $578522 | $322295 | $1862002 | $1004158 |
| Benefits and Insurance Services | 103387 | 104040 | 318292 | 309867 |
| National Practices | 11909 | 12549 | 35034 | 39168 |
| **Total Revenue** | $**693818** | $**438884** | $**2215328** | $**1353193** |
| **Gross Margin** |  |  |  |  |
| Financial Services | $94681 | $61656 | $383210 | $215149 |
| Benefits and Insurance Services | 19305 | 21075 | 64845 | 60022 |
| National Practices | 1224 | 1448 | 3603 | 4106 |
| Operating expenses - unallocated <sup>(1)</sup>: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other expense | (17234) | (3961) | (28386) | (16744) |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred compensation | (7847) | (7305) | (17132) | (18164) |
| **Total Gross Margin** | $**90129** | $**72913** | $**406140** | $**244369** |
| &nbsp;&nbsp;&nbsp;&nbsp;**As a % of Revenue** | **13.0%** | **16.6%** | **18.3%** | **18.1%** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Represents operating expenses not directly allocated to individual businesses, including stock-based compensation, consolidation and integration charges, and certain advertising expenses. "Operating expenses - unallocated" also includes gains or losses attributable to the assets held in a rabbi trust associated with the Company's deferred compensation plan. These gains or losses do not impact "Income before income tax expense" as they are directly offset by the same adjustment to "Other income (expense), net" in the Consolidated Statements of Comprehensive Income. Net gains or losses recognized from adjustments to the fair value of the assets held in the rabbi trust are recorded as compensation expense (income) in "Operating expenses" and "Corporate, general and administrative expenses," and offset in "Other income (expense), net."

Page 9 of 16

**NYSE: CBZ** ● **<u>www.cbiz.com</u>** ● X: **@cbz**

------

**CBIZ, INC.**

**<u>SELECT CASH FLOW DATA (UNAUDITED)</u>**

***(In thousands)***

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** |
| **Net income** | $**194861** | $**131761** |
| *Adjustments to reconcile net income to net cash provided by operating activities:* |  |  |
| Gain on sale of operations, net | (1124) | (4953) |
| Depreciation and amortization expense | 74313 | 28593 |
| Bad debt expense, net of recoveries | 3216 | 2099 |
| Adjustments to contingent earnout liability, net | 1984 | 6340 |
| Stock-based compensation expense | 19572 | 7431 |
| Other noncash adjustments | 14071 | 5276 |
| **Net income, after adjustments to reconcile net income to net cash provided by operating activities** | **306893** | **176547** |
| Changes in assets and liabilities, net of acquisitions and divestitures | (258047) | (108379) |
| **Net cash provided by operating activities** | **48846** | **68168** |
| **Net cash used in investing activities** | **(16913)** | **(24911)** |
| **Net cash used in financing activities** | **(75233)** | **(85222)** |
| **Net decrease in cash, cash equivalents and restricted cash** | **(43300)** | **(41965)** |
| Cash, cash equivalents and restricted cash at beginning of year | $187170 | $157148 |
| **Cash, cash equivalents and restricted cash at end of period** | $**143870** | $**115183** |
| **Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet:** | **Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet:** | **Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet:** |
| Cash and cash equivalents | $16969 | $1076 |
| Restricted cash | 44455 | 43104 |
| Cash equivalents included in funds held for clients | 82446 | 71003 |
| **Total cash, cash equivalents and restricted cash** | $**143870** | $**115183** |

---

Page 10 of 16

**NYSE: CBZ** ● **<u>www.cbiz.com</u>** ● X: **@cbz**

------

**CBIZ, INC.**

**<u>SELECT FINANCIAL DATA AND RATIOS (UNAUDITED)</u>**

***(In thousands, except percentages, DSO, and per share data)***

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **December 31, 2024** |
| Cash and cash equivalents | $16969 | $13826 |
| Restricted cash | 44455 | 38661 |
| Accounts receivable, net | 719554 | 534858 |
| Other current assets | 96655 | 72528 |
| Current assets before funds held for clients | 877633 | 659873 |
| Funds held for clients | 127782 | 175853 |
| Goodwill and other intangible assets, net | 2885727 | 2945470 |
| **Total assets** | **4545144** | **4470883** |
| Current liabilities before client fund obligations, excluding short-term debt | 447846 | 463697 |
| Client fund obligations | 127590 | 175928 |
| Total short-term debt, net | 66323 | 66177 |
| Total long-term debt, net | 1502639 | 1333755 |
| **Total liabilities** | **2673345** | **2690900** |
| Treasury stock | (1046152) | (910601) |
| **Total stockholders' equity** | **1871799** | **1779983** |
| Debt to equity | 83.8% | 78.6% |
| Days sales outstanding (DSO) <sup>(1)</sup> | 94 | 73 |
| Shares outstanding | 54104 | 50198 |
| Basic weighted average common shares outstanding | 62360 | 52375 |
| Diluted weighted average common shares outstanding | 62699 | 52661 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)DSO is provided for continuing operations and represents accounts receivable, net, at the end of the period, divided by trailing twelve-months daily revenue. The Company has included DSO data because such data is commonly used as a performance measure by analysts and investors and as a measure of the Company's ability to collect on receivables in a timely manner. DSO should not be regarded as an alternative or replacement to any measurement of performance under GAAP. DSO on September 30, 2024, was 97.

Page 11 of 16

**NYSE: CBZ** ● **<u>www.cbiz.com</u>** ● X: **@cbz**

------

**CBIZ, INC.**

**<u>GAAP RECONCILIATION</u>**

**<u>Net Income (Loss) and Diluted Earnings Per Share ("EPS") to Adjusted Net Income (Loss), Adjusted Diluted EPS and Adjusted EBITDA</u>**<sup>(1)</sup>

***(Unaudited. Amounts in thousands, except per share data)***

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** |
| | **Financial Services** | **Benefits and Insurance Services** | **National Practices** | **Corporate & Other** | **Consolidated** | **EPS** |
| **Net income (loss)** | $**94062** | $**19347** | $**2348** | $**(85611)** | $**30146** | $**0.48** |
| *Adjustments:* |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Integration costs related to acquisitions <sup>(2)</sup> | 10340 | 228 |  | 18071 | 28639 | 0.47 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | 17090 | 1658 |  |  | 18748 | 0.30 |
| &nbsp;&nbsp;&nbsp;&nbsp;Litigation gain, net <sup>(3)</sup> |  |  |  | (293) | (293) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of operations, net |  |  | (1124) |  | (1124) | (0.02) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax effect related to adjustments |  |  |  | (12635) | (12635) | (0.22) |
| **Adjusted net income (loss)** | $**121492** | $**21233** | $**1224** | $**(80468)** | $**63481** | $**1.01** |
| Interest expense |  |  |  | 27960 | 27960 |  |
| Income tax expense |  |  |  | 10260 | 10260 |  |
| Tax effect related to the adjustments above |  |  |  | 12635 | 12635 |  |
| Depreciation <sup>(4)</sup> | 4014 | 525 | 1 | 1152 | 5692 |  |
| **Adjusted EBITDA** | $**125506** | $**21758** | $**1225** | $**(28461)** | $**120028** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**As a % of Revenue** | **21.7%** | **21.0%** | **10.3%** | **N/A** | **17.3%** |  |
|  | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** |
|  | **Financial Services** | **Benefits and Insurance Services** | **National Practices** | **Corporate & Other** | **Consolidated** | **EPS** |
| **Net income (loss)** | $**61671** | $**21077** | $**6401** | $**(54065)** | $**35084** | $**0.70** |
| *Adjustments:* |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Integration costs related to acquisitions <sup>(2)</sup> | (21) |  |  | 368 | 347 | 0.01 |
| &nbsp;&nbsp;&nbsp;&nbsp;Transaction costs <sup>(5)</sup> | 42 |  |  | 14752 | 14794 | 0.29 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | 4019 | 2036 |  |  | 6055 | 0.12 |
| &nbsp;&nbsp;&nbsp;&nbsp;Litigation costs <sup>(3)</sup> |  |  |  | 543 | 543 | 0.01 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of operations, net |  |  | (4953) |  | (4953) | (0.10) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax effect related to adjustments |  |  |  | (4957) | (4957) | (0.10) |
| **Adjusted net income (loss)** | $**65711** | $**23113** | $**1448** | $**(43359)** | $**46913** | $**0.93** |
| Interest expense |  |  |  | 4968 | 4968 |  |
| Income tax expense |  |  |  | 15887 | 15887 |  |
| Tax effect related to the adjustments above |  |  |  | 4957 | 4957 |  |
| Depreciation | 1829 | 568 | 6 | 1128 | 3531 |  |
| **Adjusted EBITDA** | **67540** | **23681** | **1454** | **(16419)** | $**76256** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**As a % of Revenue** | **21.0%** | **22.8%** | **11.6%** | **N/A** | **17.4%** |  |

---

Page 12 of 16

**NYSE: CBZ** ● **<u>www.cbiz.com</u>** ● X: **@cbz**

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)This table reconciles Adjusted net income (loss), Adjusted diluted EPS, and Adjusted EBITDA to the most directly comparable GAAP financial measures. Adjusted net income (loss), Adjusted diluted EPS, and Adjusted EBITDA exclude the impact of the Transaction and other significant non-operating related gains and losses that management does not consider on-going in nature. Please refer to the 'Non-GAAP Financial Measures' section for further management discussion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)These costs include, but are not limited to, certain consulting, technology, personnel, as well as other integration costs related to acquisitions. Amounts reported for 2025 relate to the costs associated with the Transaction, and amounts reported in 2024 relate to the costs associated with the acquisitions of Erickson, Brown & Kloster, LLC and CompuData, Inc.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)During the three months ended September 30, 2025, the Company recorded a $0.3 million adjustment to the accrued legal costs associated with the $12.5 million legal settlement when payments were made. For the three months ended September 30, 2024, the costs associated with this litigation were $0.5 million. These costs were recorded in "Corporate general and administrative expenses" on the consolidated statement of comprehensive income.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)Depreciation expense reported for 2025 excluded $0.2 million of depreciation expense reported as "Integration costs related to acquisitions" above. The accelerated depreciation was associated with certain technology assets from the Transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)These costs include, but are not limited to, certain non-recurring legal and other professional service costs incurred in connection with the announced purchase of Marcum during the three months ended September 30, 2024.

Page 13 of 16

**NYSE: CBZ** ● **<u>www.cbiz.com</u>** ● X: **@cbz**

------

**CBIZ, INC.**

**<u>GAAP RECONCILIATION</u>**

**<u>Net Income (Loss) and Diluted Earnings Per Share ("EPS") to Adjusted Net Income (Loss), Adjusted Diluted EPS and Adjusted EBITDA</u>**<sup>(1)</sup>

***(Unaudited. Amounts in thousands, except per share data)***

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Nine months ended September 30, 2025** | **Nine months ended September 30, 2025** | **Nine months ended September 30, 2025** | **Nine months ended September 30, 2025** | **Nine months ended September 30, 2025** | **Nine months ended September 30, 2025** |
| | **Financial Services** | **Benefits and Insurance Services** | **National Practices** | **Corporate & Other** | **Consolidated** | **EPS** |
| **Net income (loss)** | $**382750** | $**65260** | $**4727** | $**(257876)** | $**194861** | $**3.06** |
| *Adjustments:* |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Integration costs related to acquisitions <sup>(2)</sup> | 17840 | 609 |  | 45045 | 63494 | 1.00 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | 51071 | 5133 |  |  | 56204 | 0.88 |
| &nbsp;&nbsp;&nbsp;&nbsp;Litigation gain, net <sup>(3)</sup> |  |  |  | (11356) | (11356) | (0.18) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of operations, net |  |  | (1124) |  | (1124) | (0.02) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax effect related to adjustments |  |  |  | (30151) | (30151) | (0.47) |
| **Adjusted net income (loss)** | $**451661** | $**71002** | $**3603** | $**(254338)** | $**271928** | $**4.27** |
| Interest expense |  |  |  | 80983 | 80983 |  |
| Income tax expense |  |  |  | 76234 | 76234 |  |
| Tax effect related to the adjustments above |  |  |  | 30151 | 30151 |  |
| Depreciation <sup>(4)</sup> | 11360 | 1608 | 4 | 3329 | 16301 |  |
| **Adjusted EBITDA** | $**463021** | $**72610** | $**3607** | $**(63641)** | $**475597** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**As a % of Revenue** | **24.9%** | **22.8%** | **10.3%** | **N/A** | **21.5%** |  |
|  | **Nine months ended September 30, 2024** | **Nine months ended September 30, 2024** | **Nine months ended September 30, 2024** | **Nine months ended September 30, 2024** | **Nine months ended September 30, 2024** | **Nine months ended September 30, 2024** |
|  | **Financial Services** | **Benefits and Insurance Services** | **National Practices** | **Corporate & Other** | **Consolidated** | **EPS** |
| **Net income (loss)** | $**215378** | $**60111** | $**9055** | $**(152783)** | $**131761** | $**2.62** |
| *Adjustments:* |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Integration costs related to acquisitions <sup>(2)</sup> | 236 | 169 |  | 854 | 1259 | 0.03 |
| &nbsp;&nbsp;&nbsp;&nbsp;Transaction costs <sup>(5)</sup> | 42 |  |  | 21403 | 21445 | 0.43 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | 11935 | 6083 |  | 1 | 18019 | 0.36 |
| &nbsp;&nbsp;&nbsp;&nbsp;Facility optimization costs <sup>(6)</sup> |  |  |  | 340 | 340 | 0.01 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of operations, net |  |  | (4953) |  | (4953) | (0.10) |
| &nbsp;&nbsp;&nbsp;&nbsp;Litigation costs <sup>(3)</sup> |  |  |  | 1266 | 1266 | 0.03 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax effect related to adjustments |  |  |  | (10491) | (10491) | (0.23) |
| **Adjusted net income (loss)** | $**227591** | $**66363** | $**4102** | $**(139410)** | $**158646** | $**3.15** |
| Interest expense |  |  |  | 15363 | 15363 |  |
| Income tax expense |  |  |  | 51417 | 51417 |  |
| Tax effect related to the adjustments above |  |  |  | 10491 | 10491 |  |
| Depreciation | 5410 | 1716 | 24 | 3424 | 10574 |  |
| **Adjusted EBITDA** | **233001** | **68079** | **4126** | **(58715)** | **246491** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**As a % of Revenue** | **23.2%** | **22.0%** | **10.5%** | **N/A** | **18.2%** |  |

---

Page 14 of 16

**NYSE: CBZ** ● **<u>www.cbiz.com</u>** ● X: **@cbz**

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)This table reconciles Adjusted net income (loss), Adjusted diluted EPS, and Adjusted EBITDA to the most directly comparable GAAP financial measures. Adjusted net income (loss), Adjusted diluted EPS, and Adjusted EBITDA exclude the impact of the Transaction and other significant non-operating related gains and losses that management does not consider on-going in nature. Please refer to the 'Non-GAAP Financial Measures' section for further management discussion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)These costs include, but are not limited to, certain consulting, technology, personnel, as well as other integration costs related to acquisitions. Amounts reported for 2025 relate to the costs associated with the Transaction, and amounts reported in 2024 relate to the costs associated with the acquisitions of Erickson, Brown & Kloster, LLC and CompuData, Inc.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)During the nine months ended September 30, 2025, the Company recorded a gain of $12.5 million related to a legal settlement payment from a small group of former employees. The gain was recorded in "other income (expense), net" on the consolidated statement of comprehensive income for the nine months ended September 30, 2025. The costs associated with this litigation were $1.1 million and $1.3 million, respectively, for the nine months ended September 30, 2025 and 2024, and were recorded in "Corporate general and administrative expenses" on the consolidated statement of comprehensive income.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)Depreciation expense reported for 2025 excluded $1.8 million of depreciation expense reported as "Integration costs related to acquisitions" above. The accelerated depreciation was associated with certain technology assets from the Transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)These costs include, but are not limited to, certain non-recurring legal and other professional service costs incurred in connection with the announced purchase of Marcum during the nine months ended September 30, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)These costs related to incremental non-recurring lease expenses incurred as a result of CBIZ's real estate optimization efforts.

Page 15 of 16

**NYSE: CBZ** ● **<u>www.cbiz.com</u>** ● X: **@cbz**

------

**CBIZ, INC.**

**<u>GAAP RECONCILIATION</u>**

**<u>Full Year 2025 Net Income and Diluted Earnings Per Share ("EPS") to Adjusted Net Income, Adjusted Diluted EPS, and Adjusted EBITDA Guidance</u>**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Full Year 2025 Guidance** | **Full Year 2025 Guidance** | **Full Year 2025 Guidance** | **Full Year 2025 Guidance** |
| | **(Amounts in millions except per share data)** | **(Amounts in millions except per share data)** | **(Amounts in millions except per share data)** | **(Amounts in millions except per share data)** |
| | **Low** | **Low** | **High** | **High** |
| | **Amounts** | **EPS** | **Amounts** | **EPS** |
| **GAAP Net Income** | $**127.9** | $**1.97** | $**131.1** | $**2.02** |
| Amortization of acquired intangible assets <sup>(1)</sup> | 75.1 | 1.15 | 75.1 | 1.15 |
| Integration costs related to acquisitions <sup>(2)</sup> | 75.0 | 1.15 | 75.0 | 1.15 |
| Income tax effect related to adjustments | (43.5) | (0.67) | (43.5) | (0.67) |
| **Adjusted Net Income** | $**234.5** | $**3.60** | $**237.7** | $**3.65** |
| Depreciation | 22.1 |  | 22.1 |  |
| Interest expense | 99.3 |  | 99.3 |  |
| Income tax expense included the tax effect related to the adjustments above | 94.5 |  | 97.1 |  |
| **Adjusted EBITDA** | $**450.4** |  | $**456.2** |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) These costs represent the amortization of the intangible assets, such as client lists, recognized as a result of applying Accounting Standards Codification Topic 850, Business Combinations. The amount of amortization expense recorded in each period is significantly affected by the size and timing of our acquisitions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) These costs include, but are not limited to, certain consulting, technology, personnel, as well as other operating and general administrative costs associated with the integration of the Marcum business.

**Contacts:**

Media: Amy McGahan, Director of Corporate & Strategic Communications, amy.mcgahan@cbiz.com

Investor Relations: Lori Novickis, Director, Corporate Relations, lnovickis@cbiz.com

CBIZ, Inc., Cleveland, Ohio, (216) 447-9000

Page 16 of 16

**NYSE: CBZ** ● **<u>www.cbiz.com</u>** ● X: **@cbz**